Drugs / QLC5508
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07620041 | Jun → Dec 2026 expected | refractory malignant neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07198633 | Nov 2025 → Dec 2026 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07256782 | Oct 2025 → Oct 2026 expected | neoplastic disease or syndrome | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07632690 | Jun 2026 → Jun 2028 expected | prostate cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07463573 | Apr 2026 → Jun 2028 expected | esophageal squamous cell carcinoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLC5508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07256782 ↗ |
| Modality | Other / unclassified | “B7H3 ADC” NCT07198633 ↗ |
| Route | Other | “QLC5508 will be administered by injection” NCT07198633 ↗ |